Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2014 May;67(5):420-5.
doi: 10.1136/jclinpath-2013-202052. Epub 2014 Jan 8.

TOP2A gene copy number change in breast cancer

M J Engstrøm  1 , B Ytterhus, L J Vatten, S Opdahl, A M Bofin
Affiliations
Free PMC article

TOP2A gene copy number change in breast cancer

M J Engstrøm et al. J Clin Pathol. 2014 May.
Free PMC article

Abstract

Aims: The clinical significance of TOP2A as a prognostic marker has not been clarified. The aims of this study were to investigate the frequency of TOP2A copy number change; to correlate TOP2A with HER2 status, hormone receptor (HR) status and molecular subtype, and further to explore differences in breast cancer-specific survival according to TOP2A and HER2.

Methods: In this study, TOP2A, HER2 and chromosome 17 copy number were assessed in 670 cases of breast cancer using in situ hybridisation techniques. Gene to chromosome ratios ≥2 were classified as amplification. TOP2A deletion (gene to chromosome ratio ≤0.8) or monosomy (only one signal for both gene and chromosome in more than 75% of nuclei) were classified as gene loss.

Results: A strong association between TOP2A change and HR and HER2 status was found. During the first 5 years after diagnosis, the risk of death from breast cancer was significantly higher for cases with HER2 amplification irrespective of TOP2A status.

Conclusions: TOP2A copy number change was strongly associated with HR and HER2 status and as a prognostic marker TOP2A is probably of limited value.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Classification algorithm for molecular subtyping.
Figure 2
Figure 2
Kaplan–Meier plot. Breast cancer-specific survival (BCSS) according to TOP2A. p Value from log-rank test of differences in BCSS first 5 years after diagnosis was 0.02. After 5 years, the p value was 0.4.
Figure 3
Figure 3
Kaplan–Meier plot. Breast cancer-specific survival (BCSS) according to HER2. p Value from log-rank test of differences in BCSS first 5 years after diagnosis was <0.0001. After 5 years, the p value was 0.9.
Figure 4
Figure 4
Kaplan–Meier plot. Breast cancer-specific survival (BCSS) according to TOP2A and HER2. p Value from log-rank test of differences in BCSS first 5 years after diagnosis was <0.0001. After 5 years, the p value was 1.0.
See this image and copyright information in PMC

References

    1. Fountzilas G, Dafni U, Bobos M, et al. Evaluation of the prognostic role of centromere 17 gain and HER2/topoisomerase II alpha gene status and protein expression in patients with breast cancer treated with anthracycline-containing adjuvant chemotherapy: pooled analysis of two Hellenic Cooperative Oncology Group (HeCOG) phase III trials. BMC Cancer 2013;13:163. - PMC - PubMed
    1. Jacot W, Fiche M, Zaman K, et al. The HER2 amplicon in breast cancer: Topoisomerase IIA and beyond. Biochim Biophys Acta 2013;1836:146–57 - PubMed
    1. Bofin AM, Ytterhus B, Hagmar BM. TOP2A and HER-2 gene amplification in fine needle aspirates from breast carcinomas. Cytopathology 2003;14:314–9 - PubMed
    1. Romero A, Martin M, Cheang MC, et al. Assessment of Topoisomerase II alpha status in breast cancer by quantitative PCR, gene expression microarrays, immunohistochemistry, and fluorescence in situ hybridization. Am J Pathol 2011;178:1453–60 - PMC - PubMed
    1. Engstrom MJ, Opdahl S, Hagen AI, et al. Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. Breast Cancer Res Treat 2013;140:463–73 - PMC - PubMed

Publication types

MeSH terms